There is a problem in dermatology that everyone sees and few will name openly.
A growing number of dermatologists — some prominent, some involved in teaching — are being paid by pharmaceutical and cosmetic companies to promote products on Instagram and YouTube. Not to educate. To sell. The content is scripted, the relationships are commercial, and the audience is patients who believe they are receiving independent clinical guidance.
This is not a grey area. It is a conflict of interest framed in clinical language.
Why This Matters
Medical professionalism rests on a simple foundation: a doctor’s judgment belongs to the patient, not to whoever is paying the doctor. Paid product promotion does not just strain that principle — it undermines it. The moment a clinician becomes a brand amplifier, clinical neutrality is compromised, whether or not payment is disclosed.
Disclosure does not neutralise bias. Research in behavioural ethics demonstrates that disclosure can fail to reduce — and may even normalise — conflicted advice. Studies examining physician–industry relationships have repeatedly shown associations between financial ties and prescribing patterns.
An #AD tag confirms a commercial arrangement. It does not restore independence.
The damage is threefold. Patients mistake advertising for clinical guidance. Prescribing may drift toward brands rather than evidence. And the collective reputation of the profession erodes — gradually, then visibly.
What Is Actually Happening
The formats have become increasingly sophisticated.
Paid posts are framed as education. Unboxing videos and brand tagging are presented as personal clinical experience. “Awareness campaigns” function as marketing. Consultancy arrangements operate quietly alongside public-facing endorsements.
And then there is what occurred at Dermacon 2026 in Bengaluru.
During the national conference of IADVL, a dermatologist was filmed at a pharmaceutical exhibition stall on the conference floor producing promotional content for that company. The post, tagged explicitly as advertising, was uploaded publicly within days. It remains visible. The stall belonged to a company that had paid for exhibition space at that very event.
This did not occur in ambiguity. It occurred in plain sight, within an academic conference venue.
A public comment beneath the post asked whether such product endorsement by a dermatologist is ethical at all.
That question deserves a professional answer — not a comment-section debate.
What Needs to Happen
1. Conditional Industry Eligibility Standards
Any pharmaceutical or cosmetic company that engages dermatologists for paid social media promotion should have its eligibility for the following made contingent upon compliance with clearly defined ethical marketing standards:
Sponsorship of national conferences
Exhibition space at association events
Endorsed educational collaborations
Advertising in association publications
This is not a ban. It is governance.
If paid physician promotion carries institutional consequences, the economics change. A clear definition of “paid promotional content,” a verification mechanism, and an appeals process must accompany such standards.
2. A Binding Social Media Ethics Charter
A charter — binding at minimum for office bearers, conference faculty, award recipients, and committee members — should prohibit:
Direct product endorsement for financial compensation
Brand-specific promotional testimonials
Failure to disclose industry relationships
Education and advertising must be defined separately, with examples. Ambiguity is where enforcement fails.
3. Mandatory Conflict-of-Interest Disclosure
Annual disclosure of industry payments above a defined threshold. Public listing of declared affiliations for office bearers, guideline authors, and conference speakers.
Transparency is structural, not punitive. It shifts conflicts from invisible to visible.
4. Enforceable Professional Consequences
Where violations occur, consequences should be defined in advance — loss of speaking privileges, ineligibility for leadership roles, and in serious cases, suspension of membership.
Self-regulation requires enforceability. Without it, standards are symbolic.
5. Independent Ethics Oversight
A standing ethics body with a legal advisor, a bioethicist, and an external public representative — not as decoration, but with defined authority and annual reporting responsibility.
Seniority alone is not a safeguard against conflict of interest.
6. Engagement With Regulators
Professional associations should not replace regulators. But they should engage them. Clarification from the National Medical Commission on digital endorsement rules is overdue.
If professions do not define boundaries internally, they are eventually defined externally.
7. Reform in Medical Education
Postgraduate training must explicitly address conflicts of interest, industry relationships, and digital conduct. Young dermatologists absorb norms from senior behaviour. If paid promotion is normalised at the top, that lesson transmits rapidly downward.
Ethics must be taught intentionally — not inferred passively.
Anticipated Objections
“Doctors have freedom of speech.” Freedom of speech does not override fiduciary responsibility.
“Other specialties do this too.” Ethical drift elsewhere does not justify ours.
“Disclosure is enough.” The empirical literature does not support that position. Disclosure may confirm a conflict while doing little to correct it.
“Industry collaboration is essential.” It is — for research and education. Paid brand promotion is advertising, not collaboration.
“This is a personal reputation issue.” Professional credibility is collective capital. When it is used commercially, the cost is shared across the entire profession.
The Strategic Reality
Resistance is predictable. Some benefit financially from the current arrangement. Industry relationships are deeply embedded in how conferences are funded and how speakers are chosen. Early enforcement will be tested deliberately.
None of that negates the need for standards.
Symbolic inaction signals to members that rules are decorative — and to the public that the profession is either unaware of the problem or unwilling to confront it.
What You Can Do
IADVL’s Anti-Quackery, Legal and Ethics Committee has modified its official complaint mechanism to include dermatologists engaging in product endorsement and promoting self-prescription. This is a significant step — it means the committee has formally recognised this as a category of professional concern within its mandate.
If you have witnessed conduct of this kind — whether at Dermacon 2026 or elsewhere — you may file a complaint directly through the official form:
https://forms.gle/n36zszJdNaUAguYJA
Please share this form in your state groups and local networks. Documented complaints force institutional engagement. The more the committee receives, the harder it becomes to treat this as a fringe concern.
The Closing Argument
Dermatology’s credibility cannot be protected by silence.
If commercial endorsement culture expands unchecked — including within academic conference spaces — reputational damage will be cumulative and difficult to reverse. The public does not forgive professions that appeared to know what was happening and chose not to act.
A profession that cannot regulate itself invites regulation from outside — on terms not of its choosing.
The question is not whether standards are needed.
It is whether we will set them ourselves.
Dr. Sasi Kiran Attili. MBBS. MRCP (Dermatology, UK), ICDP - UEMS International Board Certification in Dermatopathology.
Consultant Dermatologist, Cosmetic Surgeon & Dermatopathologist.
Visakha Institute of Skin & Allergy, Visakhapatnam, India.
References
Cain DM, Loewenstein G, Moore DA. The dirt on coming clean: Perverse effects of disclosing conflicts of interest. Journal of Legal Studies. 2005;34(1):1–25.
Cain DM, Loewenstein G, Moore DA. When sunlight fails to disinfect: Understanding the perverse effects of disclosing conflicts of interest. Journal of Consumer Research. 2011;37(5):836–857.
Wazana A. Physicians and the pharmaceutical industry: Is a gift ever just a gift? JAMA. 2000;283(3):373–380.
DeJong C, Aguilar T, Tseng CW, Lin GA, Boscardin WJ, Dudley RA. Pharmaceutical industry–sponsored meals and physician prescribing patterns for Medicare beneficiaries. JAMA Internal Medicine. 2016;176(8):1114–1122.
National Medical Commission. Professional Conduct Regulations. New Delhi: NMC; 2023.